SC: Exporters with Pending Applications Prior to Rule 96(10) Omission Entitled to IGST Refund  ||  Bombay HC to Scrap Law College Intake Cuts if Mumbai University Follows Prescribed Timelines  ||  Delhi HC Orders Removal of Derogatory Online Content Targeting Actress Tabu  ||  Madras HC Orders Interim Elected Panel to Manage State Bar Council Affairs Until New Committee Forms  ||  Patna HC: Whatsapp Messages Need Section 65B Certificate, Oral Evidence is Insufficient  ||  Allahabad HC: Denying Maintenance That Forces Wife into Destitution Violates Art 21 Right to Dignity  ||  Rajasthan HC Takes Suo Motu Notice of Structural Defects After IIT Bombay Warns Dome May Collapse  ||  Bombay HC: 0.1 Mg Above Alcohol Limit is Insufficient to Warrant a Drunken Driving Trial  ||  Supreme Court: Marking a Document as an Exhibit Does Not Prove its Contents  ||  Supreme Court: Unpaid Consideration Alone Does Not Invalidate a Sale Deed    

Indigenously Made Rotavirus Vaccine Received WHO Pre-qualification - (24 Jan 2018)

Law of Medicine

WHO “pre-qualified” the ROTAVAC vaccine, developed by the Hyderabad-based Bharat Biotech Limited. Now, the vaccine can be sold internationally to several countries in Africa and South America. It is a low-cost vaccine developed indigenously to protect against a deadly virus that kills about half a million children around the world every year and is rampant in Asia and Africa. ROTAVAC was developed as a result of a multi country - multi partner collaborative efforts for over 2 decades. This large public private social innovation partnership included the Government of India's Department of Biotechnology (DBT), the Indian Council of Medical Research, the Indian Institute of Science (IISC), the All India Institute of Medical Sciences (AIIMS), Christian Medical College (CMC) Vellore, King Edwards Memorial Hospital (KEM) Pune, and others.

The World Health Organisation estimates that, Rotavirus is a leading cause of severe diarrhoea in children below five and India accounts for 22 percent of deaths caused due to rotavirus diarrhoea worldwide. As per a recent study published in an international non-profit organization, PATH, 37 percent of the 578,000 childhood diarrheal deaths in 2013 were due to rotavirus, for a total of 215,000 rotavirus deaths globally. More than 90 percent of these deaths occurred in low-resource countries. ROTAVAC was licensed by the Drugs Controller General of India in the year 2014. India began a phased introduction of the vaccine in its national immunization program from 2016. Bharat Biotech a Hyderabad based company has supplied approximately 30 million doses of ROTAVAC to the Indian government till date and is aiming to providing ROTAVAC at an affordable price to public-sector markets globally to ensure that, the vaccine is accessible to all children in low-resource countries. It is estimated that, every child in the world will become infected with Rotavirus, if not vaccinated.

The development of the rotavirus vaccine would further inspire and promote high-end research and development not only in medical science, but also in other advanced areas of science and technology and an effective Public-Private-Partnership model for finding affordable solutions to societal challenges. It is noteworthy that, the development of ROTAVAC is also an evidence of a growing drug development sector in India. After a rigorous regulatory process, WHO granted pre-qualification for ROTAVAC.

Tags : VACCINE   PRE-QUALIFICATION   GRANT  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved